Nastech, Thiakis, Merck deal

MRK licensed worldwide rights to co-develop NSTK's PYY3-36 to treat obesity. The nasal spray formulation of the naturally occurring PYY hormone has completed

Read the full 235 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE